These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 32284318

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Halabi S, Jiang S, Terasawa E, Garcia-Horton V, Ayyagari R, Waldeck AR, Shore N.
    J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
    Altavilla A, Casadei C, Lolli C, Menna C, Ravaglia G, Gurioli G, Farolfi A, Brighi N, Conteduca V, Burgio SL, Schepisi G, Rossi L, Gargiulo S, Lisotti I, De Giorgi U.
    Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
    Hussain A, Jiang S, Varghese D, Appukkuttan S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Corman S.
    BMC Cancer; 2022 Mar 22; 22(1):304. PubMed ID: 35317768
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
    Tombal B, Sternberg CN, Hussain M, Ganguli A, Li Y, Sandin R, Bhadauria H, Oh M, Saad F.
    ESMO Open; 2022 Jun 22; 7(3):100510. PubMed ID: 35714477
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
    Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW.
    Curr Treat Options Oncol; 2019 Feb 11; 20(2):14. PubMed ID: 30741354
    [Abstract] [Full Text] [Related]

  • 13. Treatment and trials in non-metastatic castration-resistant prostate cancer.
    Lokeshwar SD, Klaassen Z, Saad F.
    Nat Rev Urol; 2021 Jul 11; 18(7):433-442. PubMed ID: 34002069
    [Abstract] [Full Text] [Related]

  • 14. Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
    George DJ, Morgans AK, Constantinovici N, Khan N, Khan J, Chen G, Hlebec V, Shore ND.
    JAMA Netw Open; 2024 Aug 01; 7(8):e2429783. PubMed ID: 39190308
    [Abstract] [Full Text] [Related]

  • 15. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
    Appukkuttan S, Farej R, Miles L, Purser M, Wen L.
    J Manag Care Spec Pharm; 2021 Feb 01; 27(2):166-174. PubMed ID: 33141615
    [Abstract] [Full Text] [Related]

  • 16. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.
    Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Zhang K, Lopez-Gitlitz A, Smith MR.
    Ann Oncol; 2019 Nov 01; 30(11):1813-1820. PubMed ID: 31560066
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
    Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, Özgüroğlu M, Juárez Soto Á, Merseburger AS, Uemura H, Ye D, Given R, Cella D, Basch E, Miladinovic B, Dearden L, Deprince K, Naini V, Lopez-Gitlitz A, Chi KN, TITAN investigators.
    Lancet Oncol; 2019 Nov 01; 20(11):1518-1530. PubMed ID: 31578173
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer.
    Graff JN, Liang LW, Kim J, Stenzl A.
    Future Oncol; 2021 Aug 01; 17(23):3017-3026. PubMed ID: 34044584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.